Danish pharmaceutical giant Novo Nordisk (NVO) has filed a federal lawsuit against U.S. rival Eli Lilly & Co. (LLY), alleging deceptive advertising for its competing GLP-1 therapies, escalating the brutal fight for dominance of the U.S. weight-loss drug market into a legal showdown.
Filed Tuesday morning in the U.S. District Court for the District of New Jersey, the suit claims Lilly’s marketing campaigns for diabetes drug Mounjaro and weight-loss treatment Zepbound rely on outdated clinical data that has sparked “widespread confusion” among consumers. In early trading Tuesday, Novo Nordisk shares slipped 0.41% to $49.41, while Lilly stock advanced 2.30% to $1,173.28.
At the center of the dispute is the high-profile SURMOUNT-5 head-to-head trial released in December 2024, which pitted the two companies’ flagship weight-loss injections against each other at the FDA-approved doses available at the time. The study found patients taking 10mg or 15mg of Zepbound lost an average of 20.2% of their body weight — roughly 50 pounds — over 72 weeks, compared with 13.7%, or about 33 pounds, for those on the then-maximum 2.4mg dose of Novo’s Wegovy.
Novo argues Lilly has continued to lean on those older results in nationwide advertising even after U.S. regulators cleared a far stronger 7.2mg dose of Wegovy in March 2026. In clinical testing, the higher-dose Wegovy achieved average weight loss of 19% — approximately 47 pounds — over 72 weeks, a benefit nearly identical to Zepbound’s performance in the SURMOUNT-5 trial. The Danish drugmaker describes Lilly’s refusal to update its comparative claims as “a nationwide pattern of deceptive advertising” that misleads consumers using obsolete study data.
The complaint asks the court to issue a permanent injunction forcing Lilly to remove all misleading comparative advertising across every platform, order the company to run corrective advertising to remedy the confusion, and award unspecified monetary damages.
Lilly pushed back against the allegations in a public statement, saying it “stands firmly behind our advertising.” The Indianapolis-based drugmaker noted that head-to-head clinical trials remain the “gold standard for comparing medicines,” and stressed that SURMOUNT-5 is still the only completed study to directly evaluate Wegovy and Zepbound against one another.
The legal battle unfolds against the backdrop of a U.S. GLP-1 market forecast to reach $100 billion by 2030, where Novo and Lilly have waged an increasingly bitter contest for market leadership.
Novo pioneered the category with its semaglutide molecule, launching it in the U.S. as diabetes treatment Ozempic in 2018 before introducing the weight-loss branded version Wegovy in 2021. Lilly entered the fray with its tirzepatide therapy, rolling out diabetes indication Mounjaro in 2022 and weight-loss product Zepbound the following year.
Both companies saw their valuations soar between 2018 and 2024 as the transformative weight-loss efficacy of GLP-1 drugs became widely recognized. But the SURMOUNT-5 results triggered a sharp divergence in their stock trajectories: since the trial’s release, Lilly shares have rallied 42.7%, while Novo Nordisk’s stock has tumbled 53.8%. The lawsuit has now thrust the once-settled trial narrative back into the spotlight.
Despite the dramatic legal escalation, market observers widely expect the suit to have only a limited material impact on either company’s shares or long-term outlook.
Financially, any potential damages are likely to be modest. Lilly’s comparative advertising claims were factually accurate prior to the approval of Wegovy’s higher dose in March, and the company generated $10.4 billion in free cash flow over the past 12 months, putting any financial penalty well within its means.
On the competitive front, a court ruling barring Lilly from claiming Zepbound delivers superior weight loss would deliver a tactical win for Novo, helping to erode the prevailing market perception that Lilly’s drug is the more effective option. Yet given Lilly’s substantial marketing budget and resources, the company is widely expected to quickly pivot to alternative advertising strategies, leaving the broader competitive landscape largely intact.
All told, the lawsuit represents the latest flare-up in one of pharma’s most lucrative and hard-fought markets, but is unlikely to meaningfully alter the fundamental trajectory of either company’s business or stock performance.
